Calimmune
Calimmune was a clinical-stage gene therapy company founded in 2006 in Pasadena, California, co-founded by Nobel laureate David Baltimore. Venture-backed by Alexandria and RA Capital Management, it was acquired by CSL Behring for $400 million in 2017.
- Company typePrivate
- Founded2006
- HeadquartersPasadena, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Calimmune firmographics
Firmographics- Name
- Calimmune
- Website
- https://calimmune.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Calimmune was a clinical-stage gene therapy company founded in 2006 in Pasadena, California, co-founded by Nobel laureate David Baltimore. Venture-backed by Alexandria and RA Capital Management, it was acquired by CSL Behring for $400 million in 2017.
- Ownership category
- akta.pro rank
Calimmune industry classification
Industry- Product category
- Gene Therapy Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro industry
- Lentiviral Vector Gene Therapy DevelopersCell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Keywords
Where Calimmune is headquartered
LocationHeadquarters
- HQ city
- Pasadena
- HQ country
- United States
- HQ region
- North America
Markets served
Calimmune business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Calimmune product offering
Product offeringCore offering
Calimmune was a clinical-stage gene therapy company developing lentiviral vector-based cell and gene therapies for serious diseases, with primary focus on HIV/AIDS and related therapeutic areas. The company advanced proprietary ex vivo gene modification candidates through clinical development before being acquired by CSL Behring in 2017.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical-stage gene therapy pipeline (lentiviral vector-based candidates) Calimmune's clinical-stage gene therapy candidates targeted serious diseases, with the lead program focused on HIV/AIDS using a proprietary lentiviral vector-based ex vivo gene modification approach. These were therapeutic candidates in development rather than marketed products, intended for eventual commercialization or partnership post-acquisition by CSL Behring.
Companies that use Calimmune
Customer profileIdeal customer profiles1 record
Calimmune technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Calimmune partnerships and signals
Strategic signalScale indicators1 record
Calimmune competitors and assessment
Company assessmentEmerging players
- Editas Medicine: Editas is a clinical-stage genome editing company using CRISPR/Cas systems — an emerging alternative modality to lentiviral gene therapy for similar target diseases. Relevant as a next-generation competitor that could displace or complement lentiviral platforms.
- CRISPR Therapeutics: CRISPR Therapeutics is a leading clinical-stage CRISPR/Cas9 gene editing company (e.g., CASGEVY for sickle cell disease). Comparable to Calimmune in targeting hematologic diseases via ex vivo cell modification, though via editing rather than lentiviral gene addition.
Direct peers
- uniQure: uniQure is a clinical-stage gene therapy company developing therapies using viral vectors (notably AAV, with prior lentiviral experience) for rare and serious diseases. It is comparable as a vector-based gene therapy peer addressing similar regulatory and clinical complexity.
- Sangamo Therapeutics: Sangamo is a clinical-stage gene therapy company with programs in genome editing (zinc finger nucleases) and gene regulation, historically active in HIV gene therapy. It overlaps with Calimmune's gene therapy approach and HIV therapeutic focus.
- Oxford BioMedica: Oxford BioMedica is a leading lentiviral vector developer and CDMO, comparable to Calimmune through shared lentiviral vector platform technology used in gene and cell therapy. Its dual role as platform developer and clinical-stage company makes it a tight direct peer.
- Voyager Therapeutics: Voyager Therapeutics is a clinical-stage gene therapy company developing AAV-based treatments for CNS diseases. Comparable to Calimmune as a vector-based gene therapy developer in clinical stages with a focused pipeline.
- bluebird bio: bluebird bio is a clinical-stage gene therapy company that, like Calimmune, developed lentiviral vector-based therapies targeting hematopoietic stem cells (e.g., for sickle cell disease and beta-thalassemia). It is the most directly comparable peer given its lentiviral modality, target cell type, and clinical-stage profile.
Broad incumbents
- CSL Behring: CSL Behring is the global biotech that acquired Calimmune in 2017. It is a broad incumbent in plasma-derived and biologic therapies, and now owns Calimmune's lentiviral gene therapy assets — relevant as the acquirer and continued developer of the platform.
Market position
Customer concentration
Calimmune social profiles
Digital presenceCalimmune financial estimates
Financial estimateRevenue estimate
Valuation estimate
Calimmune leadership team
Management profileNumber of profiles
Profiles1 record
Calimmune funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Calimmune M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Calimmune
What does Calimmune do?
Calimmune was a clinical-stage gene therapy company developing lentiviral vector-based cell and gene therapies for serious diseases, with primary focus on HIV/AIDS and related therapeutic areas. The company advanced proprietary ex vivo gene modification candidates through clinical development before being acquired by CSL Behring in 2017.
Is Calimmune a public or private company?
Calimmune is a private company. It is classified as venture growth investor backed and is currently acquired.
When was Calimmune founded?
Calimmune was founded in 2006. It employs 1 to 10 people.
Where is Calimmune based?
Calimmune is headquartered in Pasadena, United States, in the North America region.
Who are Calimmune's main competitors?
Emerging players on record are Editas Medicine and CRISPR Therapeutics. Direct peers are uniQure, Sangamo Therapeutics, Oxford BioMedica, Voyager Therapeutics and bluebird bio. CSL Behring is listed as a broad incumbent.
Does Calimmune have an API?
No public API is recorded for Calimmune.
What industry is Calimmune in?
Calimmune's product category is Gene Therapy Development. Its primary akta.pro industry code is HLAAACAB, Lentiviral Vector Gene Therapy Developers, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714.